Robert W. Simms, MD
Professor
Boston University School of Medicine
Dept of Medicine
Rheumatology (Arthritis)

MD, University of Rochester School of Medicine & Dentistry




Dr. Simms is the Rheumatology Section Chief at Boston University School of Medicine. His major research interest is in scleroderma clinical outcome measures and clinical trials. He is the most active scleroderma clinician in the section, and is the site PI on multiple past and ongoing multicenter trials. He partners with Dr. Lafyatis in clinical and translational studies. This has included a recently completed trial of rituximab in systemic sclerosis. He works very closely with Dr. Farber on clinical issues as well as clinical trial initiatives in pulmonary hypertension. Dr. Simms receives NIH support as the site PI on a multi-center trial of high dose immunosuppressive therapy and autologous bone marrow transplant compared to cyclophosphamide (SCOT).


Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis
09/22/2017 - 08/31/2022 (PI)
University of Pittsburgh NIH NIAMS
2P50AR060780-06A1

Protocol # ITN075AI, (BRAVOS) - Evaluation of Brentuximab Vedotin in Diffuse Cutaneous Systemic Sclerosis
02/01/2017 - 05/31/2021 (PI)
Benaroya Research Institute at Virginia Mason NIH NIAID
5UM1AI109565-05

Protocol # ML30172 - Scleroderma Lung Study III: Combining of anti-fibrotic effects of Pirfenidone with Mycophenolate to treat scleroderma-related interstitial lung disease
06/29/2018 - 02/28/2021 (PI)
University of California, Los Angeles


Protocol # 1199.225, An open-label extension trial to assess the long term safety of nintedanib in patients with‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD)
02/08/2018 - 02/07/2021 (PI)
Boehringer Ingelheim Pharmaceuticals


A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
10/18/2017 - 10/17/2020 (PI)
Corbus Pharmaceuticals Holdings, Inc.


Protocol #LTI-301 - A Phase 3 Open-Label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients
02/21/2018 - 02/20/2020 (PI)
Liquidia Technologies, Inc.


Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
01/01/2018 - 12/31/2019 (PI)
University of Pittsburgh NIH NIAMS
5R21AR069285-02

United States Pulmonary Hypertension Scientific Registry
10/11/2016 - 12/31/2019 (PI)
United States Pulmonary Hypertension Scientific Registry


US-based, observation, drug registry of Opsumit (macitentan) new users in clinical practice
01/16/2015 - 12/08/2019 (PI)
Actelion Pharmaceuticals, Ltd.


A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
12/01/2015 - 11/30/2019 (PI)
Corbus Pharmaceuticals Holdings, Inc.


Showing 10 of 50 results. Show All Results



Yr Title Project-Sub Proj Pubs
2015 NIAMS: CORT 5P50AR060780-05 73
2015 Rheumatic Diseases Research Core Centers 5P30AR061271-05 49
2015 Core B Clinical Core 5P50AR060780-05-7136 73
2013 Core B Clinical Core 5P50AR060780-03-7136 73
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Johnson ME, Franks JM, Cai G, Mehta BK, Wood TA, Archambault K, Pioli PA, Simms RW, Orzechowski N, Arron S, Whitfield ML. Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skin. Arthritis Res Ther. 2019 Feb 06; 21(1):49. PMID: 30728065.
     
  2. Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, MacKenzie Ross RV, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respir Med. 2019 Mar; 7(3):227-238. PMID: 30527956.
     
  3. Hsu VM, Chung L, Hummers LK, Shah A, Simms R, Bolster M, Hant FN, Silver RM, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Saketkoo LA, Salazar CR, Steen VD. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol. 2019 Feb; 46(2):176-183. PMID: 30275260.
     
  4. Mantero JC, Kishore N, Ziemek J, Stifano G, Zammitti C, Khanna D, Gordon JK, Spiera R, Zhang Y, Simms RW, Lafyatis R. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial. Clin Exp Rheumatol. 2018 Jul-Aug; 36 Suppl 113(4):146-149.View Related Profiles. PMID: 30277862.
     
  5. Rice LM, Mantero JC, Stratton EA, Warburton R, Roberts K, Hill N, Simms RW, Domsic R, Farber HW, Layfatis R. Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther. 2018 08 16; 20(1):185.View Related Profiles. PMID: 30115106.
     
  6. Fleury M, Belkina AC, Proctor EA, Zammitti C, Simms RW, Lauffenburger DA, Snyder-Cappione JE, Lafyatis R, Dooms H. Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis. Arthritis Rheumatol. 2018 Apr; 70(4):566-577.View Related Profiles. PMID: 29245183.
     
  7. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018 01 04; 378(1):35-47. PMID: 29298160.
     
  8. Gorlova OY, Li Y, Gorlov I, Ying J, Chen WV, Assassi S, Reveille JD, Arnett FC, Zhou X, Bossini-Castillo L, Lopez-Isac E, Acosta-Herrera M, Gregersen PK, Lee AT, Steen VD, Fessler BJ, Khanna D, Schiopu E, Silver RM, Molitor JA, Furst DE, Kafaja S, Simms RW, Lafyatis RA, Carreira P, Simeon CP, Castellvi I, Beltran E, Ortego N, Amos CI, Martin J, Mayes MD. Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. PLoS One. 2018; 13(1):e0189498.View Related Profiles. PMID: 29293537.
     
  9. Messemaker TC, Chadli L, Cai G, Goelela VS, Boonstra M, Dorjée AL, Andersen SN, Mikkers HMM, van 't Hof P, Mei H, Distler O, Draisma HHM, Johnson ME, Orzechowski NM, Simms RW, Toes REM, Aarbiou J, Huizinga TW, Whitfield ML, DeGroot J, de Vries-Bouwstra J, Kurreeman F. Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic Sclerosis. J Invest Dermatol. 2018 04; 138(4):826-835. PMID: 29179949.
     
  10. Toyama T, Looney AP, Baker BM, Stawski L, Haines P, Simms R, Szymaniak AD, Varelas X, Trojanowska M. Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis. J Invest Dermatol. 2018 01; 138(1):78-88.View Related Profiles. PMID: 28870693.
     
Showing 10 of 92 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 92 publications over 29 distinct years, with a maximum of 8 publications in 1996 and 2014 and 2016

YearPublications
19882
19901
19913
19922
19931
19946
19952
19968
19983
19992
20001
20011
20024
20031
20041
20062
20073
20081
20095
20102
20112
20122
20134
20148
20154
20168
20175
20187
20191
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Scleroderma
Contact for Mentoring:


75 E. Newton St Evans Building
Boston MA 02118
Google Map


Simms's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department